Fatty acid amide hydrolase (FAAH) inhibition emerges as a mechanistically distinct approach to complement GLP-1 receptor agonists in obesity treatment. This enzyme degrades both appetite-stimulating endocannabinoids like anandamide and appetite-suppressing N-acylethanolamines, particularly oleoylethanolamide (OEA). By blocking FAAH, researchers can prolong OEA signaling, which activates PPARα and GPR119 pathways to enhance fat burning and improve liver lipid processing. This represents a fundamentally different mechanism from direct cannabinoid receptor antagonism, which failed clinically due to severe psychiatric side effects. The FAAH approach offers more nuanced control over endogenous lipid signaling without the broad receptor blockade that proved problematic. However, this strategy faces a critical paradox: FAAH doesn't discriminate between beneficial and harmful substrates, making tissue selectivity crucial for therapeutic success. While preclinical models show promise for enhancing GLP-1 secretion and metabolic efficiency, human data remains sparse. The real innovation lies not in FAAH inhibition as monotherapy, but as part of combination regimens addressing the plateau effects and gastrointestinal limitations of current incretin therapies. This represents incremental but potentially valuable progress in obesity pharmacotherapy.